» Articles » PMID: 10533448

Adjuvant Chemotherapy After Curative Resection for Gastric Cancer in Non-Asian Patients: Revisiting a Meta-analysis of Randomised Trials

Overview
Journal Eur J Cancer
Specialty Oncology
Date 1999 Oct 26
PMID 10533448
Citations 95
Authors
Affiliations
Soon will be listed here.
Abstract

Unlabelled: The aim of this study was to assess whether adjuvant chemotherapy after curative resection of gastric cancer increases survival rates.

Data Sources: MEDLINE (1966-1999), CancerLit (1983-1999), bibliographies, personal reprint files, and review articles were searched for relevant articles. Studies had to be randomised controlled trials of adjuvant chemotherapy versus observation following curative resection of stomach cancer that took place in non-Asian countries. Two reviewers independently evaluated the trials for eligibility, quality assessment and data abstraction, 13 trials met the eligibility criteria. The odds ratio for death in the treated group was 0.80 (95% confidence interval (CI) 0.66-0.97), corresponding to a relative risk of 0.94 (95% CI 0.89-1.00). Subgroup analyses showed a trend towards a larger magnitude of the effect when analysis was restricted to trials in which at least 2/3 of patients had node-positive disease. Our results suggest that adjuvant chemotherapy may produce a small survival benefit of borderline statistical significance in patients with curatively resected gastric carcinoma. Continued trials to find and confirm an effective adjuvant strategy are warranted.

Citing Articles

The Prognostic Value of Postoperative Lymph Node Ratio in Gastric Adenocarcinoma Patients Treated With Neoadjuvant Chemotherapy.

Sakin A, Atci M, Aldemir M, Akagunduz B, Sahin S, Arici S Cureus. 2021; 13(4):e14639.

PMID: 34046274 PMC: 8140955. DOI: 10.7759/cureus.14639.


Promoter Methylation of DNA Repair Genes Predicts Disease-free Survival of Gastric Adenocarcinoma after Adjuvant Radiotherapy.

An N, Yu Z, He X, Zhao Y, Yu L, Zhang Y Mol Ther Oncolytics. 2020; 18:109-117.

PMID: 32671186 PMC: 7334297. DOI: 10.1016/j.omto.2020.06.006.


Impact of minimally invasive gastrectomy on use of and time to adjuvant chemotherapy for gastric adenocarcinoma.

Farrow N, Freischlag K, Adam M, Blazer D J Surg Oncol. 2020; 121(3):486-493.

PMID: 31919862 PMC: 7006544. DOI: 10.1002/jso.25834.


Five-year outcomes of a phase II study of adjuvant chemotherapy with S-1 plus docetaxel for stage III gastric cancer after curative D2 gastrectomy (OGSG1002).

Fujitani K, Tamura S, Kimura Y, Matsuyama J, Imamura H, Yamamoto K Gastric Cancer. 2019; 23(3):520-530.

PMID: 31667688 DOI: 10.1007/s10120-019-01023-w.


Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial.

Ito S, Ohashi Y, Sasako M BMC Cancer. 2018; 18(1):449.

PMID: 29678146 PMC: 5910584. DOI: 10.1186/s12885-018-4341-6.